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Spontaneous reversion 
Ichthyosis with confetti (IWC) is characterized by many con-
fetti spots that appear across the body surface. The spots, which 
increase in number and size with time, exhibit normal histology. 
Choate and colleagues recently found that DNA from the rever-
tant skin patches from six IWC patients showed a single large 
segment of loss of heterozygosity on chromosome 17q. These 
findings not only indicated that the confetti spots are the result 
of loss of a dominant mutation via mitotic recombination but 
also localized the disease locus to the 34.5- to 37.7-Mb inter-
val on 17q. Further examination of the DNA sequence in this 
region revealed that frameshift mutations in KRT10, the gene 
that encodes keratin 10, cause IWC. The identified mutations 
yield an arginine-rich C-terminal peptide that results in mislo-
calization of K10 to the nucleolus and ultimately disrupts the 
keratin filament network. Although the underlying mechanism 
for such frequent reversion is not clear, revertant stem cell clones 
may be under strong positive selection or IWC cells may under-
go increased mitotic recombination. (Science 330:94–7, 2010) 
Selected by A. Blauvelt
Inspect the DRESS
Drug reaction with eosinophilia and systemic symptoms 
(DRESS) is a serious drug-induced adverse reaction that involves 
skin eruptions, fever, facial edema, polyadenopathy, and viscer-
al involvement and occurs primarily in response to anticonvul-
sants, the antigout medication allopurinol, and the antibiotics 
minocycline and the sulfamides. In addition, reactivation of 
herpes-family viruses has been reported at the onset of DRESS. 
Recent investigations by Picard and colleagues demonstrated 
that this reaction results from cutaneous and systemic manifesta-
tions of a CD8+ T-cell immune response directed against herpes-
virus antigens. Epstein–Barr virus-specific CD8+ T lymphocytes 
that secreted tumor necrosis factor-α and IFN-γ were detected 
in the blood and involved organs. These results describe a viral 
mechanistic basis behind this reaction and suggest that herpes-
virus reactivation be tested in patients with possible DRESS. (Sci 
Transl Med 2:46–62, 2010) Selected by A. Blauvelt
Drug-tolerant persisters
The development of successful cancer therapy has been 
thwarted by the relatively rapid acquisition of cancer drug resis-
tance by individual cancer cells. Although a variety of mecha-
nisms for potential genetic alterations in resistance have been 
proposed, recent findings suggest that acquired resistance to 
cancer drugs may stem from a reversible “drug-tolerant” state. 
In support of this notion, Sharma and colleagues detected 
a small subpopulation of reversibly drug-tolerant cells that 
remained viable while the majority of human cancer cells 
were killed. This increased viability requires engagement of 
IGF-1 receptor signaling and the histone demethylase KDM5A. 
Because these cells were detected at a higher frequency than 
expected because of mutational mechanisms, an epigenetic 
regulation mechanism is likely. The drug-resistant phenotype 
was acquired de novo and relinquished by individual cells at 
a low frequency. This feature suggests dynamic regulation of 
phenotypic heterogeneity of cancer cells in order to protect the 
cell population from eradication by lethal drug exposure. (Cell 
141:69–80, 2010) Selected by M. Herlyn
B-RAF blockade
Because B-RAF is the most frequently mutated protein kinase 
in human cancers, including melanoma, inhibition of B-RAF 
kinase activity offers a potential avenue for therapy. Bollag and 
colleagues have described the scaffold-based drug discovery 
of a selective inhibitor of oncogenic B-RAF kinase activity, 
PLX4032. This molecule blocked downstream extracellular 
signal–related kinase (ERK) phosphorylation and cell prolifera-
tion exclusively in BRAF-mutant cell lines. In xenograft experi-
ments, PLX4032 exhibited dose-dependent inhibition of tumor 
growth. Pharmacology studies revealed no toxicity in rats or 
beagles, and this wide safety margin supported the initiation 
of Phase I clinical trials in cancer patients using a micropre-
cipitated bulk powder form that increased drug bioavailabil-
ity in patients. In these trials, more than 80% inhibition of 
cytoplasmic ERK phosphorylation in the tumors was noted, 
and this inhibition correlated with tumor regression in BRAF-
mutant, advanced-stage, metastatic melanoma patients. Thus, 
the excellent safety and efficacy profile of this novel drug may 
offer improved treatment options for BRAF-mutant melanoma 
patients. (Nature 467:596–9, 2010) Selected by M. Herlyn
Autoantibody identity
Autoantibodies in sera from patients with the devastating 
multi organ autoimmune syndrome paraneoplastic pemphigus 
(PNP) bind to stratified complex and simple epithelia and myo-
cardium. Although some of the target antigens, such as the 
plakin family members and desmogleins, have been identified, 
an unidentified protein with Mr 170,000 (p170) is also 
immuno precipitated with PNP autoantibodies from keratino-
cyte extracts. Schepens and colleagues recently utilized 
immunoprecipitation and mass spectrometry to identify this 
protein as α-2-macroglobulin-like-1 (A2ML1). PNP auto-
antibody recognition of this broad-range protease inhibitor 
was sensitive to reducing agents, implicating conformation-
dependent epitopes. In addition, PNP autoantibodies were 
found to target mainly the amino-terminal half of this protein. 
These results implicate a novel class of proteins as the target of 
autoantibodies in patients suffering from PNP and suggest that 
autoantibodies to the A2ML1 protease inhibitor may contrib-
ute to tissue damage by aggravating inflammation. (PLoS ONE 
5:e12250, 2010)  Selected by M. Amagai
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